Ming Yi
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 43
- Cancer Immunotherapy and Biomarkers 26
- CAR-T cell therapy research 8
- Immunology 29
- Immune Cell Function and Interaction 12
- Immune cells in cancer 9
- Immunotherapy and Immune Responses 8
- Co-authors
- Kongming Wu (67 shared papers)Mengke Niu (24 shared papers)Shuang Qin (17 shared papers)Suxia Luo (16 shared papers)Qian Chu (26 shared papers)Anping Li (14 shared papers)Shuangli Zhu (10 shared papers)Shengnan Yu (7 shared papers)
- Journals
- Journal of Hematology & Oncology (16 papers)Experimental Hematology and Oncology (10 papers)Molecular Cancer (8 papers)Journal of Membrane Science (7 papers)Frontiers in Immunology (5 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Ming Yi
176 papers receiving 11.8k citations
Ming Yi's Hit Papers
Peers
Comparison fields: 5 of 166
- Oncology 4.3k
- Immunology 3.0k
- Cancer Research 1.3k
- Water Science and Technology 959
- Molecular Biology 2.9k
Countries citing papers authored by Ming Yi
This map shows the geographic impact of Ming Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Yi more than expected).
Fields of papers citing papers by Ming Yi
This network shows the impact of papers produced by Ming Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Yi. The network helps show where Ming Yi may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming Yi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 183 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combination strategies with PD-1/PD-L1 blockade: current advances and future directions Hit paper breakdown → | 2022 | 1053 |
| 2 | Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Hit paper breakdown → | 2019 | 937 |
| 3 | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors Hit paper breakdown → | 2018 | 627 |
| 4 | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment Hit paper breakdown → | 2019 | 518 |
| 5 | Regulation of PD-L1 expression in the tumor microenvironment Hit paper breakdown → | 2021 | 496 |
| 6 | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Hit paper breakdown → | 2022 | 338 |
| 7 | 2019 | 323 | |
| 8 | Polyamide-based membranes with structural homogeneity for ultrafast molecular sieving Hit paper breakdown → | 2022 | 308 |
| 9 | 2018 | 288 | |
| 10 | 2019 | 260 | |
| 11 | 2019 | 230 | |
| 12 | Recent advances in targeted strategies for triple-negative breast cancer Hit paper breakdown → | 2023 | 228 |
| 13 | 2020 | 198 | |
| 14 | 2001 | 188 | |
| 15 | The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 Hit paper breakdown → | 2021 | 180 |
| 16 | 2020 | 178 | |
| 17 | 2022 | 172 | |
| 18 | Exploiting innate immunity for cancer immunotherapy Hit paper breakdown → | 2023 | 159 |
| 19 | 2018 | 157 | |
| 20 | 2020 | 150 |
About Ming Yi
Ming Yi is a scholar working on Oncology, Immunology, Water Science and Technology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 183 papers that have together received 12.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (26 papers), Membrane Separation Technologies (18 papers), Immune Cell Function and Interaction (12 papers), Membrane-based Ion Separation Techniques (9 papers), Immune cells in cancer (9 papers), CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (8 papers) and Membrane Separation and Gas Transport (7 papers). The work is most often cited by research in Oncology (4.3k citations), Immunology (3.0k citations), Cancer Research (1.3k citations), Water Science and Technology (959 citations) and Molecular Biology (2.9k citations). Ming Yi has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Kongming Wu, Mengke Niu, Shuang Qin, Suxia Luo, Qian Chu, Anping Li, Shuangli Zhu, Shengnan Yu, Linping Xu and Dechao Jiao. Their work appears in journals such as Journal of Hematology & Oncology, Experimental Hematology and Oncology, Molecular Cancer, Journal of Membrane Science and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.